Cargando…

Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle

Respiratory syncytial virus (RSV) G glycoprotein has recently reemerged as a vaccine antigen due to its ability to elicit potent neutralizing antibodies and ameliorate disease in animal models. Here we designed three constructs to display the G central conserved domain (Gcc) focused on inducing broa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rainho-Tomko, Jennifer N., Pavot, Vincent, Kishko, Michael, Swanson, Kurt, Edwards, Darin, Yoon, Heesik, Lanza, Lilibeth, Alamares-Sapuay, Judith, Osei-Bonsu, Robert, Mundle, Sophia T., Murison, Dave A., Gallichan, Scott, Delagrave, Simon, Wei, Chih-Jen, Zhang, Linong, Nabel, Gary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244890/ https://www.ncbi.nlm.nih.gov/pubmed/35773301 http://dx.doi.org/10.1038/s41541-022-00487-9

Ejemplares similares

Effect of genetic background and delivery route on the preclinical properties of a live attenuated RSV vaccine
por: Groppo, Rachel, et al.
Publicado: (2018)

Transient opening of trimeric prefusion RSV F proteins
por: Gilman, Morgan S. A., et al.
Publicado: (2019)

Adjuvant Selection for Influenza and RSV Prefusion Subunit Vaccines
por: Isaacs, Ariel, et al.
Publicado: (2021)

2755. Phase 1/2, First-in-Human Study of the Safety, Tolerability, and Immunogenicity of an RSV Prefusion F-Based Subunit Vaccine Candidate
por: Schmoele-Thoma, Beate, et al.
Publicado: (2019)

Protection of calves by a prefusion-stabilized bovine RSV F vaccine
por: Zhang, Baoshan, et al.
Publicado: (2017)

Fusing safety and efficacy: A maternal bivalent RSV prefusion F vaccine
por: Miller, Ann M., et al.
Publicado: (2023)

1632. Bivalent RSV Prefusion F-Based Subunit Vaccine Generates High Neutralizing Titers in Older Adults
por: Fukushima, Yasushi, et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

A human antibody potently neutralizes RSV by targeting the conserved hydrophobic region of prefusion F
por: Yi, Chunyan, et al.
Publicado: (2023)

Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18–50 Years and RSV-Seropositive Children 12–24 Months
por: Stuart, Arabella S V, et al.
Publicado: (2022)

A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism
por: Krarup, Anders, et al.
Publicado: (2015)

Improved epitope resolution of the prefusion trimer-specific antibody AM14 bound to the RSV F glycoprotein
por: Harshbarger, Wayne, et al.
Publicado: (2021)

The respiratory syncytial virus (RSV) prefusion F‐protein functional antibody repertoire in adult healthy donors
por: Andreano, Emanuele, et al.
Publicado: (2021)

Characterization of a Prefusion-Specific Antibody That Recognizes a Quaternary, Cleavage-Dependent Epitope on the RSV Fusion Glycoprotein
por: Gilman, Morgan S. A., et al.
Publicado: (2015)

High-Purity Preparation of HSV-2 Vaccine Candidate ACAM529 Is Immunogenic and Efficacious In Vivo
por: Mundle, Sophia T., et al.
Publicado: (2013)

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons
por: Ison, Michael G, et al.
Publicado: (2023)

CX3CR1 Is Expressed in Differentiated Human Ciliated Airway Cells and Co-Localizes with Respiratory Syncytial Virus on Cilia in a G Protein-Dependent Manner
por: Jeong, Kwang-Il, et al.
Publicado: (2015)

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine
por: Peterson, James T, et al.
Publicado: (2021)

A Protective and Safe Intranasal RSV Vaccine Based on a Recombinant Prefusion-Like Form of the F Protein Bound to Bacterium-Like Particles
por: Rigter, Alan, et al.
Publicado: (2013)

Adenovector 26 encoded prefusion conformation stabilized RSV-F protein induces long-lasting Th1-biased immunity in neonatal mice
por: van der Fits, Leslie, et al.
Publicado: (2020)

Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
por: Lamichhane, Pramila, et al.
Publicado: (2022)

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination
por: Schwarz, Tino F, et al.
Publicado: (2022)

Immunogenicity of an AS01-adjuvanted respiratory syncytial virus prefusion F (RSVPreF3) vaccine in animal models
por: Bouzya, Badiaa, et al.
Publicado: (2023)

Architecture of the SARS coronavirus prefusion spike
por: Beniac, Daniel R, et al.
Publicado: (2006)

1942. Potential Public Health Impact of Bivalent Respiratory Syncytial Virus Prefusion F (RSVpreF) Maternal Vaccine for Prevention of RSV among US Infants
por: Hanau, Ahuva, et al.
Publicado: (2023)

Immunogenicity of RSV F DNA Vaccine in BALB/c Mice
por: Eroglu, Erdal, et al.
Publicado: (2016)

Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza Vaccine
por: Falsey, Ann R, et al.
Publicado: (2021)

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)
por: Ison, Michael G, et al.
Publicado: (2022)

Safety and Immunogenicity of a Live Attenuated RSV Vaccine in Healthy RSV-Seronegative Children 5 to 24 Months of Age
por: Malkin, Elissa, et al.
Publicado: (2013)

ChAd155-RSV vaccine is immunogenic and efficacious against bovine RSV infection-induced disease in young calves
por: de Jong, Rineke, et al.
Publicado: (2022)

Immunogenicity and Efficacy of Intramuscular Replication-Defective and Subunit Vaccines against Herpes Simplex Virus Type 2 in the Mouse Genital Model
por: Delagrave, Simon, et al.
Publicado: (2012)

Generation of a monoclonal antibody reactive to prefusion myocytes
por: Kurisaki, Tomohiro, et al.
Publicado: (2011)

The prefusion structure of herpes simplex virus glycoprotein B
por: Vollmer, B., et al.
Publicado: (2020)

Prefused lysosomes cluster on autophagosomes regulated by VAMP8
por: Chen, Qixin, et al.
Publicado: (2021)

Influenza and respiratory syncytial virus (RSV) vaccines for infants: Safety, immunogenicity, and efficacy
por: Beeler, Judy A., et al.
Publicado: (2013)

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level
por: Comeaux, Christy A, et al.
Publicado: (2022)

Safety and Immunogenicity of the Respiratory Syncytial Virus Vaccine RSV/ΔNS2/Δ1313/I1314L in RSV-Seronegative Children
por: Karron, Ruth A, et al.
Publicado: (2020)

An RSV Live-Attenuated Vaccine Candidate Lacking G Protein Mucin Domains Is Attenuated, Immunogenic, and Effective in Preventing RSV in BALB/c Mice
por: Roe, Molly K, et al.
Publicado: (2022)

Structure and immune recognition of trimeric prefusion HIV-1 Env
por: Pancera, Marie, et al.
Publicado: (2014)

Crystal structure of the prefusion surface glycoprotein of the prototypic arenavirus LCMV
por: Hastie, Kathryn M., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_mqo0q7c6vqtc037ahkscvn8cuq